119 results
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in any criminal proceeding or a penalty imposed by a regulatory authority for non-compliance with any requirement of a regulatory nature, (iii
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
, damages, reasonable legal costs and other reasonable expenses of any nature whatsoever. 1.73 “Clinical Study Report” means the final clinical study report … Know-How and other proprietary information and data of any kind, including of a financial, scientific, commercial or technical nature
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some … ”). The process for doing this depends, among other things, on the nature of the medicinal product.
The centralized procedure results in a single marketing
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
nature of the disease. And the very high bar and challenge is to actually get meaningful results in these patients. So we're provided at ASH, actually … the patients, given the unforeseen nature and the challenges that many of these institutions were facing. And with that, actually making sure we can keep
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
et al. Nature Medicine 2019 Fast off-rate CD19 binder with fast off-rate Designed for increased activity and reduced toxicity Developing Next
8-K
EX-99.1
vxcnee9e8s
14 Mar 24
Results of Operations and Financial Condition
12:32pm
D
f4s28ckvap1u9cdtcx2y
23 Feb 24
Exempt offering of security
5:28pm
8-K
EX-99.1
hdy629i
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
r20rok b4
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
5l7gpioxi0h x49
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-1.1
ggm6miz8z7rze p7y8t
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
yuiq6gi2ng4bqcqu2
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
pzd10eowurosg0p
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
04u34pa2 0meh
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.7
mu9mrt2w858gpj 4ye2
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.2
d4kub19mpij5
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
EX-10.2
1bb9ia nq48w
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-10.1
eyp4co1bjagg
9 Nov 23
Quarterly report
4:18pm
10-Q
glnj ammyt
9 Nov 23
Quarterly report
4:18pm
S-8
9yf 1msqmk
3 Nov 23
Registration of securities for employees
4:02pm